NETosis and Nucleosome Biomarkers in Septic Shock and Critical COVID-19 Patients: An Observational Study.


Journal

Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414

Informations de publication

Date de publication:
27 07 2022
Historique:
received: 23 05 2022
revised: 22 07 2022
accepted: 23 07 2022
entrez: 26 8 2022
pubmed: 27 8 2022
medline: 30 8 2022
Statut: epublish

Résumé

Background: Neutrophil extracellular traps’ (NETs’) formation is a mechanism of defense that neutrophils deploy as an alternative to phagocytosis, to constrain the spread of microorganisms. Aim: The aim was to evaluate biomarkers of NETs’ formation in a patient cohort admitted to intensive care unit (ICU) due to infection. Methods: Forty-six septic shock patients, 22 critical COVID-19 patients and 48 matched control subjects were recruited. Intact nucleosomes containing histone 3.1 (Nu.H3.1), or citrullinated histone H3R8 (Nu.Cit-H3R8), free citrullinated histone (Cit-H3), neutrophil elastase (NE) and myeloperoxidase (MPO) were measured. Results: Significant differences in Nu.H3.1 and NE levels were observed between septic shock and critical COVID-19 subjects as well as with controls (p-values < 0.05). The normalization of nucleosome levels according to the neutrophil count improved the discrimination between septic shock and critical COVID-19 patients. The ratio of Nu.Cit-H3R8 to Nu.H3.1 allowed the determination of nucleosome citrullination degree, presumably by PAD4. Conclusions: H3.1 and Cit-H3R8 nucleosomes appear to be interesting markers of global cell death and neutrophil activation when combined. Nu.H3.1 permits the evaluation of disease severity and differs between septic shock and critical COVID-19 patients, reflecting two distinct potential pathological processes in these conditions.

Identifiants

pubmed: 36008932
pii: biom12081038
doi: 10.3390/biom12081038
pmc: PMC9405965
pii:
doi:

Substances chimiques

Biomarkers 0
Histones 0
Nucleosomes 0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Déclaration de conflit d'intérêts

Among the authors, M.H., L.R. and J.C. are employees of Belgian Volition SRL and L.M., C.D., C.B. and J.D. are employees of QUALIblood s.a. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cell Host Microbe. 2010 Nov 18;8(5):445-54
pubmed: 21075355
Crit Care Med. 2021 Mar 1;49(3):e219-e234
pubmed: 33555780
J Cell Biol. 2010 Nov 1;191(3):677-91
pubmed: 20974816
Int J Infect Dis. 2012 Jul;16(7):e558-64
pubmed: 22609014
Blood. 2012 Aug 9;120(6):1157-64
pubmed: 22611154
Front Immunol. 2021 Feb 01;12:622738
pubmed: 33597956
Cell Rep. 2020 May 5;31(5):107602
pubmed: 32375035
Ann Allergy Asthma Immunol. 2021 Mar;126(3):217-218
pubmed: 33161155
Front Immunol. 2018 Sep 27;9:2147
pubmed: 30319615
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
PLoS Pathog. 2009 Oct;5(10):e1000639
pubmed: 19876394
FASEB J. 2008 Dec;22(12):4077-84
pubmed: 18753248
Emerg Microbes Infect. 2020 Dec;9(1):727-732
pubmed: 32196410
Blood. 2020 Sep 3;136(10):1169-1179
pubmed: 32597954
J Thromb Haemost. 2008 Mar;6(3):415-20
pubmed: 18088344
Clin Infect Dis. 2022 Feb 11;74(3):479-489
pubmed: 33988226
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
BMJ Open. 2017 Sep 27;7(9):e017046
pubmed: 28963294
Chin J Traumatol. 2022 Jan;25(1):17-24
pubmed: 34815141
Front Pharmacol. 2021 Aug 05;12:708302
pubmed: 34421600
PLoS One. 2019 Jul 8;14(7):e0218946
pubmed: 31283757
Blood. 2019 May 16;133(20):2178-2185
pubmed: 30898862
Crit Care Med. 2009 May;37(5):1649-54
pubmed: 19325482
Front Med (Lausanne). 2022 Jan 17;8:780750
pubmed: 35111777
Front Mol Biosci. 2021 Mar 18;8:600881
pubmed: 33816549
Sci Rep. 2018 Oct 15;8(1):15228
pubmed: 30323221
Front Med (Lausanne). 2021 Aug 16;8:666629
pubmed: 34485324
Nat Rev Immunol. 2018 Feb;18(2):134-147
pubmed: 28990587
Science. 2004 Mar 5;303(5663):1532-5
pubmed: 15001782
J Cyst Fibros. 2021 Mar;20(2):346-355
pubmed: 32727663
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
Blood. 2008 Mar 15;111(6):3070-80
pubmed: 18182576
Front Immunol. 2021 Jul 21;12:720109
pubmed: 34367190
Science. 2004 Oct 8;306(5694):279-83
pubmed: 15345777
Epidemiology. 1990 Jan;1(1):43-6
pubmed: 2081237
Clin Chem Lab Med. 2001 Jul;39(7):596-605
pubmed: 11522104

Auteurs

Laure Morimont (L)

Research and Development Department, Qualiblood s.a., 5000 Namur, Belgium.
Namur Thrombosis and Hemostasis Center, Namur Research Institute for Life Sciences, Department of Pharmacy, University of Namur, 5000 Namur, Belgium.

Mélanie Dechamps (M)

Cardiovascular Intensive Care, Cliniques Universitaires St Luc, 1200 Brussels, Belgium.
Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1200 Brussels, Belgium.

Clara David (C)

Research and Development Department, Qualiblood s.a., 5000 Namur, Belgium.

Céline Bouvy (C)

Research and Development Department, Qualiblood s.a., 5000 Namur, Belgium.

Constant Gillot (C)

Namur Thrombosis and Hemostasis Center, Namur Research Institute for Life Sciences, Department of Pharmacy, University of Namur, 5000 Namur, Belgium.

Hélène Haguet (H)

Namur Thrombosis and Hemostasis Center, Namur Research Institute for Life Sciences, Department of Pharmacy, University of Namur, 5000 Namur, Belgium.

Julien Favresse (J)

Namur Thrombosis and Hemostasis Center, Namur Research Institute for Life Sciences, Department of Pharmacy, University of Namur, 5000 Namur, Belgium.
Department of Laboratory Medicine, Clinique St Luc Bouge, 5004 Namur, Belgium.

Lorian Ronvaux (L)

Namur Thrombosis and Hemostasis Center, Namur Research Institute for Life Sciences, Department of Pharmacy, University of Namur, 5000 Namur, Belgium.
Belgian Volition SRL, Parc Scientifique Crealys, 5032 Isnes, Belgium.

Julie Candiracci (J)

Belgian Volition SRL, Parc Scientifique Crealys, 5032 Isnes, Belgium.

Marielle Herzog (M)

Belgian Volition SRL, Parc Scientifique Crealys, 5032 Isnes, Belgium.

Pierre-François Laterre (PF)

Cardiovascular Intensive Care, Cliniques Universitaires St Luc, 1200 Brussels, Belgium.

Julien De Poortere (J)

Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1200 Brussels, Belgium.

Sandrine Horman (S)

Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1200 Brussels, Belgium.

Christophe Beauloye (C)

Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain, 1200 Brussels, Belgium.
Division of Cardiology, Cliniques Universitaires St Luc, 1200 Brussels, Belgium.

Jonathan Douxfils (J)

Research and Development Department, Qualiblood s.a., 5000 Namur, Belgium.
Namur Thrombosis and Hemostasis Center, Namur Research Institute for Life Sciences, Department of Pharmacy, University of Namur, 5000 Namur, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH